Protalix BioTherapeutics‘ investigational therapy PRX-102 (pegunigalsidase alfa) improved kidney function in Fabry disease patients, according to preliminary Phase 3 clinical results. The company announced that additional positive preliminary data of its BRIDGE clinical trial will be presented during the Canadian Symposium on Lysosomal Diseases, taking place Oct. 5-6 in Sherbrooke,…
News
Roughly half of the patients diagnosed with Fabry disease experience white matter lesions, which tend to develop earlier in males and are more prevalent as patients get older, a review study shows. The study, “Development and clinical consequences of white matter lesions in Fabry disease: a systematic review,”…
Fabry disease patients struggle with physical exercise — measured by a cardiopulmonary exercise test — due to an impairment in cardiac function as a direct consequence of Fabry-associated heart disease, a study shows. The study, “Cardiopulmonary fitness assessment on maximal and submaximal exercise testing in patients with Fabry disease,”…
Renal insufficiency in Fabry disease patients may lead to cellular events that result in cardiovascular disease, a study shows. The study, “Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy,” was published in the journal Frontiers in Cardiovascular Medicine. Fabry disease patients are unable to produce an…
Inflammation of the heart, known as myocarditis, is found in more than half of patients with Fabry disease cardiomyopathy — a consequence of fat molecule accumulation in the cells of the heart — and is associated with disease severity, a study has found. Myocarditis may also limit the impact…
A new diagnostic tool that can screen for up to six lysosomal storage disorders, including Fabry disease, in newborns is now available in the United States. PerkinElmer, the kit’s developer, received U.S. Food and Drug Administration (FDA) clearance for commercial use of its NeoLSD MSMS Kit to…
Japanese researchers have used stem cells from Fabry patients to create an innovative laboratory model that mimics heart disease in a culture dish. They are now planning to use this in vitro disease model as a screening system to promote drug discovery and to improve the prognosis of patients with Fabry…
The U.S. Food and Drug Administration has granted accelerated approval to Galafold (migalastat) 123 mg capsules to treat adults with a confirmed diagnosis of Fabry disease who have an amenable galactosidase alpha gene (GLA) mutation. “This FDA approval of Galafold is a transformative moment for people in the U.S. living…
In a preclinical animal study, JCR Pharmaceuticals’ biosimilar candidate JR-051 was seen to be as effective as the approved therapy Fabrazyme (agalsidase beta) at reducing levels of globotriaosylceramide (Gb3), a fat molecule that accumulates in Fabry disease. The study’s results add to previous Phase 2/3 clinical data and suggest that JR-051…
Women with Fabry disease can suffer from significant disease that affects several organs, and should be closely monitored for possibly starting enzyme replacement therapy, recent research shows. The study, “Major Organic Involvement in Women with Fabry Disease in Argentina,” was published in the Scientific World Journal. Fabry disease…
Recent Posts
- Common Fabry symptoms often mimic IBS in adults
- Two of my sons share what it’s like having three siblings with Fabry
- Idorsia outlines new Phase 3 program for lucerastat in Fabry disease
- Jeff’s Journey With Fabry Disease
- Eye vessel abnormalities may signal heart disease in Fabry patients
- We need more oral Fabry disease treatment options that reduce pain
- AMT-191 shows promise, but safety concerns prompt dosing pause
- Guest Voice: Believe us when we say we’re having a bad day
- Sangamo starts FDA submission seeking approval of Fabry gene therapy
- Managing my hypertension has required some trial and error